Trump Signs 100% Pharmaceutical Tariff EO — China's $80B API Export Industry in Crosshairs

President Trump signed an executive order on April 2 imposing 100% tariffs on patented pharmaceutical products and active pharmaceutical ingredients (API) under Section 232 of the Trade Expansion Act. China produces approximately 80% of the world's API supply, making the order a direct pressure point on China's chemical and pharmaceutical export industry. A 120-day implementation window applies to large companies; 180 days for smaller firms. Reduced rates of 15–20% are available for allied-country suppliers (EU, Japan, Korea, Switzerland) and companies committing to US manufacturing onshoring. The order exempts orphan drugs and animal health products. The pharmaceutical tariff represents the latest front in the broader US technology and supply-chain decoupling strategy, extending pressure beyond semiconductors and AI into pharmaceutical supply chains that the COVID-19 pandemic exposed as dangerously concentrated in China. Beijing's Ministry of Commerce condemned the move as 'protectionist unilateralism' and signaled potential retaliatory measures targeting US pharmaceutical companies operating in China.